Letter sent to Healthcare Professionals: Gliolan (5-aminolevulinic acid, 5-ALA)

Letter advises that re-administration of 5-ALA on same day should be avoided as no data are available on the safety or specificity of fluorescence. False negative and false positive results may also occur with use of 5-ALA for intraoperative visualisation of malignant glioma.

Medac